
Global M&A trends in health industries: 2025 outlook
Health industries dealmakers gear up for a more favourable M&A environment in 2025.
As one of world’s largest professional services firms, PwC offers you the benefits of experience gained from working with a wide range of clients, a global network of firms with industry dedicated professionals and an extraordinary depth and breadth of services.
Pharmaceutical and Life Sciences companies are facing unprecedented challenges globally and must have the scientific, commercial, and operational capabilities necessary to thrive in an increasingly complex health care environment and emerge stronger. We work with organisations across the industry value chain - from Biotech to Big Pharma and from CRO to Medical Device - to innovate, thrive and grow, from strategy through execution.
PwC's pharmaceuticals and life sciences practice helps pharmaceutical, biotech and medical device clients develop future-focused business strategies and to implement the time critical programmes and procedures essential to success within worldwide regulatory frameworks.
PwC’s global network of pharmaceutical, biotech and medtech experts works with you to define and deliver effective solutions to the complex challenges affecting your business in all areas from innovation to regulation and patient engagement.
We work closely with our clients to formulate a new strategy for success and achieve increased performance by improving the efficiency and effectiveness of the company’s R&D operations. We help our clients evaluate their R&D Strategy and Portfolio Management, improve management and control, and identify cost saving initiatives.
Health industries dealmakers gear up for a more favourable M&A environment in 2025.
With a confluence of factors pointing towards significant deal opportunities in 2025, industry players must remain agile and ready.
Sujay Shetty
PwC Global Health Industries Advisory Leader, India Health Industries Leader, PwC India